ORGENESIS INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-20: Form 8-K; Period of report 2018-12-20; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2018-12-14: Form 8-K; Period of report 2018-12-10; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2018-12-06: Form 8-K; Period of report 2018-11-30; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2018-11-28: Form 8-K; Period of report 2018-11-21; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-20 | 8-K | 2018-12-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8k.htm |
| 2018-12-14 | 8-K | 2018-12-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02. | form8k.htm |
| 2018-12-06 | 8-K | 2018-11-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02. | form8k.htm |
| 2018-11-28 | 8-K | 2018-11-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02. | form8k.htm |
| 2018-11-20 | 8-K | 2018-11-13 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02. | form8k.htm |
| 2018-10-29 | 8-K | 2018-10-29 | 7.01 Regulation FD Disclosure | 7.01 Orgenesis Inc. has prepared an investor presentation to be used in connection with general corporate presentations, a copy which is attached to this Current Report on Form 8-K as Exhibit 99.1. | form8k.htm |
| 2018-10-29 | 8-K | 2018-10-29 | 8.01 Other Events | 8.01 On October 16, 2018, Orgenesis Inc. (the “Company”) entered into a collaboration agreement with Immugenyx, LLC (“Immugenyx”), a wholly owned subsidiary of Hemogenyx Pharmaceuticals Plc (LSE: HEMO). | form8k.htm |
| 2018-10-25 | 8-K | 2018-10-25 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On October 22, 2018, the Board of Directors (the “Board”) of Orgenesis Inc. (the “Company”) approved a change to the Company’s fiscal year end from November 30 to December 31 of each year. 5.07 On October 23, 2018, the Company held its 2018 annual meeting of stockholders (the “2018 Annual Meeting”) at 10:00 a.m. at the offices of Pearl Cohen Zedek Latzer Baratz LLP at 1500 Broadway, New York, NY. | form8k.htm |
| 2018-07-20 | 8-K | 2018-07-19 | 7.01 Regulation FD Disclosure | 7.01 A copy of a presentation that is intended to be used by representatives of Orgenesis Inc. (the “Company”) in meetings with prospective investors and other parties is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | form8k.htm |
| 2018-07-17 | 8-K | 2018-07-17 | 2.02 Results of Operations and Financial Condition | 2.02 On July 17, 2018, Orgenesis Inc. (the “Company”) issued a press release announcing its results of operations and financial condition as well as a business update for the quarter ended May 31, 2018. | form8k.htm |
| 2018-07-05 | 8-K | 2018-06-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 28, 2018, the compensation committee (the “Committee”) of the board of directors of Orgenesis Inc. (the “Company”) amended the Company’s 2017 Equity Incentive Plan (the “Plan”) to remove the limit on the number of common stock-based rights that may be awarded by the Committee during any fiscal year to an eligible participant. | form8k.htm |
| 2018-06-29 | 8-K | 2018-06-29 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.01 The disclosures set forth above in Item 1.01 of this Current Report on Form 8-K are incorporated herein by reference. 3.02 The disclosures set forth above in Item 1.01 of this Current Report on Form 8-K are incorporated herein by reference. | form8k.htm |
| 2018-06-25 | 8-K | 2018-06-25 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On June 19, 2018, Orgenesis Inc. (the “Company” or “Orgenesis”) and Mircod Limited, a company formed under the laws of Cyprus (“Mircod”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) for the research, development and commercialization of potential key technologies related to biological sensing for Orgenesis’s clinical development and manufacturing projects (the “Development Project”). | form8k.htm |
| 2018-05-18 | 8-K | 2018-05-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 14, 2018, the compensation committee of the Board of Directors of Orgenesis Inc. (the "Company") approved a grant of options under the Company’s 2017 Equity Incentive Plan (the “2017 Plan”) to Denis Bedoret, the General Manager of MaSTherCell S.A., to purchase 15,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). | form8k.htm |
| 2018-04-30 | 8-K | 2018-04-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 25, 2018, Mr. Hugues Bultot resigned from the Board of Directors ("Board") of Orgenesis Inc. ("Company"), effective immediately. | form8k.htm |
| 2018-03-21 | 8-K | 2018-03-16 | 3.02 Unregistered Sales of Equity Securities | 3.02 On March 16, 2018, Orgenesis Inc. (the “Company”) entered into definitive agreements with accredited investors relating to a private placement (the “Private Placement”) of (i) 798,803 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) three year warrants (the “Investor Warrants”) to purchase up to an additional 798,803 shares of the Company’s Common Stock at a per share exercise price of $6.24. | form8k.htm |
| 2018-01-24 | 8-K | 2018-01-23 | 8.01 Other Events | 8.01 On January 22, 2018, Orgenesis Inc. (the “Company”) issued a press release announcing the strategic organization regrouping of the Company’s CDMO global manufacturing service offerings. | form8k.htm |
| 2018-01-09 | 8-K | 2018-01-09 | 7.01 Regulation FD Disclosure | 7.01 Orgenesis Inc. (the “Company”) will be conducting meetings at the Biotech Showcase in San Francisco, California, being held on January 8-10, 2018. | form8k.htm |